ALS News Today Home | ALS News Today
3 天之前 · Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic lateral sclerosis (ALS) and similar disorders. The U.S. patent grants Avicenna exclusive rights to pharmaceutical products containing inhibitors of the Rho associated protein kinases 1 and 2 (ROCK1/2). It also….
The stages of amyotrophic lateral sclerosis (ALS) - ALS News Today
2024年6月13日 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder marked by progressively worsening stages of progression.People with ALS experience muscle weakness and neurological dysfunction, but initial symptoms are typically mild and affect only one part of the body. As the disease becomes more and more severe, these issues gradually spread to the entire body, affecting a range of ...
Types of Amyotrophic Lateral Sclerosis (ALS) – ALS News Today
2023年3月8日 · Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that can be classified into different types based on factors like genetics, a patient’s family history, and the disorder’s early symptoms. Across all types, ALS is marked by the loss of motor neurons, the nerve cells that control voluntary muscle movements ...
Largest ALS patient-based stem cell, biodata resource now open
1 天前 · by Lindsey Shapiro, PhD November 21, 2024. Answer ALS and Cedars-Sinai have made openly available their amyotrophic lateral sclerosis (ALS) patient-based stem cell and biodata repository to researchers worldwide. The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized ...
News Archives - ALS News Today
Ontario commits CA$13 million to address ALS community needs. The government of Ontario has committed CA$13 million (around $9.36 million) over three years to provide critical and comprehensive care to people with amyotrophic lateral sclerosis (ALS) who live in the Canadian province. The funding, which was announced in Ontario’s 2024 Fall ...
Tiziana wins funding for small clinical trial in ALS of intranasal ...
1 天前 · The upcoming trial intends to investigate the safety and effectiveness of two foralumab doses in 20 ALS patients. It builds on positive findings from multiple sclerosis (MS) patients, in whom the intranasal antibody therapy significantly decreased neuroinflammation and stabilized or reduced disability levels. Tiziana now wants to see if foralumab might also help in ALS.
PrimeC in ALS patients shown to extend complication-free survival
by Andrea Lobo, PhD March 4, 2024. Treatment with NeuroSense Therapeutics’ PrimeC was found to extend patients’ time without complications or death, and to lead to clinically meaningful effects on quality of life, among those with amyotrophic lateral sclerosis (ALS). The new data comes from the PARADIGM Phase 2b study (NCT05357950), a fully ...
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
2023年8月28日 · Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). It will be AKV9’s first-in-human study and is ...
What is Amyotrophic Lateral Sclerosis (ALS)? | ALS News Today
2023年3月20日 · FAQs. Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder that damages nerve cells and causes disability. The condition also is known as Lou Gehrig’s disease, after the famed New York Yankees baseball player who was diagnosed with the disorder in the late 1930s. ALS specifically damages motor neurons, the nerve cells ...
First-in-human trial of ALS therapy ASHA-624 expected in early 2025
2 天之前 · A newly awarded grant from the ALS Association will support Asha Therapeutics ‘ work to advance ASHA-624, a small molecule being developed for amyotrophic lateral sclerosis (ALS), into a first-in-human clinical trial that’s expected to begin early next year. The grant was through the Lawrence and Isabel Barnett Drug Development Program ...